Dr. Yi Lu obtained his Ph.D. from Sichuan University in 2006. After graduation, he joined the faculty of School of Pharmacy, Fudan University and was promoted to associate professor in 2011. Dr. Lu focuses on the oral drug delivery system and development of novel pharmaceutical technologies. Specifically, he designed lipid based drug delivery systems to improve the oral bioavailability of poorly soluble drugs; he developed fluid-bed coating technique for the industrial preparation of cyclodextrine inclusion complexes and solid dispersions as well as solidification of liquid formulations such as SMEDDS and micelles; he introduced interior gelation strategy to improve the in vitro and in vivo stability of liposomes. Also he invented acid-base neutralization technique for the preparation of nanocrystals. Until now, Dr. Lu publishes more than 60 SCI papers with 2 authorized patents.
Drug delivery; Oral; Transdermal
Education
2001.9-2006.7 Ph.D. program
Department of Pharmaceutics, West China School of Pharmacy, Sichuan University, Chengdu, PR China. Research Topic: Study on the transdermal and target drug delivery system of vincristine and its mechanism of transport. Supervisor: Prof. Shixiang Hou.
1997.8-2001.7 B.S. program
West China School of Pharmacy, Sichuan University, Chengdu, PR China.
Professional Experiences
2011.9-present Associate Professor, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, PR China.
2014.3-2015.3 Visting Scholar, Purdue University, USA.
2006.7-2011.8 Lecture, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, PR China.
Teaching Activities
For Undergraduate Students
Pharmaceutics I, Pharmaceutics II, Introduction to Pharmaceutics
For Graduate Students
Experimental Design and Optimization in Pharmaceutical Sciences, Frontier in Cross-discipline of Pharmaceutics
Grants & Projects
1. PI, Study on new mechanisms in nanocrystal preparation by nucleation from metastable solution triggered by high velocity jet homogenization (16ZR1403500), Shanghai Natural Science Foundation, 2016.07-2019.06;
2. PI, Thermosensitive gelation of liposome interior (30801440), National Science Foundation Committee, 2009.1-2011.12; Co-PI, Study on the transdermal and target drug delivery system of anti-cancer constituents in Chinese Materia Medica and its mechanism of transport (30472194), National Science Foundation Committee, 2005.1-2007.12;
3. PI, Mechanic study on cubic nanoparticles to enhance the oral absorption of poorly water-soluble drugs (200802461092), Doctoral Fund of Ministry of Education of China, 2009.1-2011.12
4. PI, Enhanced oral absorption of water-insoluble drugs by mixed micelle precursors (0852nm04400). Shanghai Municipal Committee of Science and Technology, 2008.10-2010.9
5. Co-PI (in charge of preparation development), Preclinical study on a typeⅠchemical new drug, pyrroloquinoline quinone trilithium, for prophylaxis and treatment of Alzheimer's disease (2011ZX09102-003-04), National Major Scientific and Technological Special Project for “Significant New Drugs Development”, 2011.01-2013.12
6. Co-PI, Enhanced oral bioavailability of poorly water-soluble drugs by solidified self-nanoemulsifying drug delivery systems (0952nm03200). Shanghai Municipal Committee of Science and Technology, 2009.7-2011.9
7. Co-PI, Study on the liver targeting of recombined HDL nanoparticle mediated by apo A-I and its mechanism of action (0952nm03500). Shanghai Municipal Committee of Science and Technology, 2009.7-2011.9
8. PI, Evaluation on the in vitro transdermal transportation of Aminolevulinic Acid Hydrochloride for Topical Powder, Fudan Zhangjiang Bio-pharm Co. Ltd..
9. Co-PI, Lymphatic absorption by the oral route: rationale design of delivery systems exemplified by self-microemulsifying and micellar drug delivery systems. F. Hoffmann-La Roche Ltd.
10. Co-PI, Solid dispersion of polypeptides: enhanced formulation stability and oral bioavailability of insulin. Novo Nordisk A/S.
11. Co-PI, Transfersome as Potential Oral Insulin Drug Delivery Systems: Protransfersome Concept and Mechanistic Study. Novo Nordisk A/S
Memberships
Pharmaceutics Committee member, Shanghai Association of Pharmacy (2016-)
Biologic Particuology Committee member, Chinese Society of Particuology (2014-)
Youth Member of Council, Chinese Society of Particuology (2012-)
Dermatopharmacology Committee member, Shanghai Association of Pharmacology (2012-)
Editorial Board Member, Journal of Basic and Clinical Pharmacy (2016-)
Editorial Board Member, Journal of Pharmaceutical Research (2015-)
Invited Presentations
1. Yi Lu, research progress on transdermal drug delivery system and strategies enhancing transdermal permeation. 2018. Annual Meeting of Dermatopharmacology Committee of Shanghai Association of Pharmacology, Shanghai.
2. Yi Lu, Study on in vivo fate of nanocrystals via oral route using self-discriminating fluorescent hybrid nanocrystals. 2017. Forums for Advanced Materials by Chinese Chemical Letters, Xining.
3. Yi Lu, Application of ACQ probe in studies on performing mechanisms of nano drug delivery systems, 2016. Annual Meeting of Chinese Society of Particuology, Chengdu.
4. Yi Lu, Control on particle size and size distribution during bottom-up process, 2015. The second National Symposium on Bbiological Particles, Guangzhou.
5. Yi Lu, Ning Tang, Wei Wu. Stability of Phytomedicine: Comparative study on stability of Silymarine and Silybin in buffered solution and biosamples. 2007. Symposium of China Association of Chinese Medicine on Chinese Traditional Patent Medicine, Haerbin.
Selected Publications
1. Yike Xie, Baokui Shi, Fei Xia, Jianping Qi, Xiaochun Dong, Weili, Zhao, Tonglei Li, Wei Wu, Yi Lu*. Epithelia transmembrane transport of orally administered ultrafine drug particles evidenced by environment sensitive fluorophores in cellular and animal studies. J Control Release, 2018, 270:65-75
2. Chengying Shen, Yinqian Yang, Baode Shen, Yike Xie, Jianping Qi, Xiaochun Dong, Weili Zhao, Weifeng Zhu, Wei Wu, Hailong Yuan* and Yi Lu*. Self-discriminating fluorescent hybrid nanocrystals: efficient and accurate tracking of translocation via oral delivery. Nanoscale, 2018, 10, 436–450
3. Zhongjian Chen, Yongjiu Lu, Jianping Qi, Quangang Zhu, Yi Lu*, Wei Wu. Overcoming or circumventing the stratum corneum barrier for efficient transcutaneous immunization. Drug Discov Today, 2018, 23(1):181-186.
4. Qin Yu, Xiying Wu, Quangang Zhu, Wei Wu, Zhongjian Chen*, Ye Li*, Yi Lu*, Enhanced transdermal delivery of meloxicam by nanocrystals: preparation, in vitro and in vivo evaluation. Asian J Pharm Sci, 2017, https://doi.org/10.1016/j.ajps.2017.10.004
5. Bo Wan, Yikang Dai, Dailei Liu, Jianping Qi, Xiaochun Dong, Weili Zhao, Wei Wu*, and Yi Lu*, Intraocular Fate of Polycaprolactone Nanoparticles Administered via Intravitreal and Various Periocular Routes: Bioimaging of Integral Nanoparticles Using Environment-Sensitive Fluorophores. J Biomed Nanotech, 2017, 13, 960-972
6. Yi Lu, Jianping Qi, Xiaochun Dong, Weili Zhao, Wei Wu, The in vivo fate of nanocrystals. Drug Discov Today, 2017, 22 (4), 744-750.
7. Ejaj Ahmad, Yunhai Feng, Jianping Qi, Wufa Fan, Yuhua Ma, Haisheng He, Fei Xia, Xiaochun Dong, Weili Zhao, Yi Lu* and Wei Wu*. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale, 2017,9, 1174-1183
8. Yike Xie, Zhongjian Chen, Rui Su, Ye Li, Jianping Qi, Wei Wu, Yi Lu*. Preparation and Optimization of Amorphous Ursodeoxycholic Acid Nanosuspensions by Nanoprecipitation based on Acid-base Neutralization for Enhanced Dissolution. Curr Drug Deliver, 2017, 14(4): 483-491
9. Ma Y, He H, Xia F, Li Y, Lu Y, Chen D, Qi J, Lu Y*, Zhang W*, Wu W*. In vivo fate of lipid-silybin conjugate nanoparticles: Implications on enhanced oral bioavailability. Nanomedicine. 2017, 13(8):2643-2654.
10. Yuhua Ma, Haisheng He, Wufa Fan, Yingxia Li, Wei Zhang, Weili Zhao, Jianping Qi, Yi Lu*, Xiaochun Dong*, and Wei Wu*. In Vivo Fate of Biomimetic Mixed Micelles as Nanocarriers for Bioavailability Enhancement of Lipid?Drug Conjugates. ACS Biomater Sci Eng., 2017, 3 (10): 2399-2409
11. Xie YC, Hu XW, He HS, Xia F, Ma YH, Qi JP, Dong XC, Zhao WL, Lu Y*, Wu W*. Tracking translocation of glucan microparticles targeting M cells: implications for oral drug delivery. J Mater Chem B. 2016;4(17):2864-2873.
12. Lu Y, Li Y, Wu W*. Injected nanocrystals for targeted drug delivery. Acta Pharm Sin B. 2016;6(2):106-113.
13. Yi Lu, Yan Chen, Richard A. Gemeinhart, Wei Wu, Tonglei Li*. Developing Nanocrystals for Cancer Treatment. Nanomedicine (Lond) 2015, 10(16): 2537-2552.
14. Xiuli Wei, Yi Lu*, Jianping Qi, Baojian Wu, Jian Chen, Huinan Xu, Wei Wu. An in situ crosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin. Drug Deliv 2015, 22(3): 298-305.
15. Yi Lu, Yiting Qiu, Jianping Qi, Meiqing Feng, Dianwen Ju, Wei Wu*. Biomimetic reassembled chylomicrons as novel association model for the prediction of lymphatic transportation of highly lipophilic drugs via the oral route. Int J Pharm 2015, 483: 69-76.
16. Lu Y, Tang N, Lian R, Qi J, Wu W. Understanding the relationship between wettability and dissolution of solid dispersion. Int J Pharm. 2014, 465(1-2):25-31.
17. Mette Thing, Yi Lu*, Li ?g?rdh, Claus Larsen, Jesper ?stergaard, Wei He, Wei Wu, Frank Larsen, Susan Weng Larsen*. Prolonged naproxen joint residence time after intra-articular injection of lipophilic solutions comprising a naproxen glycolamide ester prodrug in the rat. Int J Pharm 2013, 451(1-2):34-40.
18. Fuxia Dong, Yi Lu*, Yunchang Xie, Jianping Qi, Fuqiang Hu, Sanming Li*, Wei Wu. Bile salts/phospholipids mixed micelle pellets precursor prepared by fluid-bed coating. Int J Nanomedicine 2013, 8: 1653-1663.
Patents
1. Yi Lu, Wei Wu, Fuxia Dong, Jianping Qi. Solid dispersion for poorly water-soluble drugs containing phospholipids and bile salts and its preparation methods. Granted. ZL 201010293523.1.
2. Wei Wu, Yan Lei, Yi Lu, Jianping Qi. Solid preparation containing poorly water-soluble drugs and its preparation methods. Granted. 201110085318.0.
